Business Overview

McKesson Corporation is one of the largest healthcare companies in the United States and operates primarily as a pharmaceutical distributor — the high-volume middleman that buys drugs from manufacturers and delivers them to pharmacies, hospitals, clinics, and other care providers. Alongside its drug distribution business, McKesson supplies medical-surgical products, provides specialty pharmaceutical and oncology services, and offers technology, data, and outsourcing services to drug makers, providers, and payers. It is one of the "big three" U.S. drug distributors alongside Cencora (formerly AmerisourceBergen) and Cardinal Health, a structure that gives the three of them control over the vast majority of the prescription drugs that flow through the country.

The way McKesson earns money is the most important thing to understand about it: distribution is a razor-thin-margin, enormous-revenue business. The company books the full value of the drugs passing through its network as revenue, but it keeps only a tiny fraction as gross profit, earning money on the spread between buy and sell prices, on distribution and service fees negotiated with manufacturers, and on volume-based incentives. Reported segments typically include U.S. Pharmaceutical (the core distribution engine and biggest revenue contributor), Prescription Technology Solutions (RxTS, which connects manufacturers, pharmacies, and patients with access and affordability tools), Medical-Surgical Solutions (distribution to physician offices, post-acute, and home care), and International operations. Specialty pharmaceuticals — expensive oncology and complex drugs distributed through businesses like its oncology platform — have become an increasingly important profit driver.

Financial Trends

McKesson's financial profile is defined by very large top-line revenue paired with very thin margins. Because the company recognizes the full price of distributed drugs as revenue, its sales figures rank among the highest of any U.S. company, but operating and net margins measured against that revenue are extremely small. Investors should not judge McKesson by margin percentage the way they would a software or consumer company; the business runs on scale, inventory turnover, working-capital efficiency, and consistent fee income.

• Growth drivers: rising prescription volumes, an aging population, branded and specialty drug price inflation, and the continued shift toward high-cost specialty and oncology therapies, which tend to carry better economics than commodity generics.
• Margin and mix: profitability is heavily influenced by the mix of branded vs. generic drugs, generic sourcing economics, and the growth of higher-value services in RxTS and specialty/oncology.
• Capital structure: the business is capital-light relative to revenue but carries significant working capital tied up in inventory and receivables, partly offset by large payables to manufacturers. Cash generation tends to be strong and steady.
• Capital returns: McKesson has a long history of returning cash to shareholders through substantial share repurchases and a growing dividend, which steadily reduces share count over time.
• Litigation overhang: historically, results have been affected by large charges and multi-year settlement payments related to opioid litigation, which flow through cash flow over an extended period.

What to Watch in the Filings

Because the headline revenue number is so large and the margins so thin, the detail in McKesson's filings matters more than the totals. When reading the 10-K and 10-Q, focus on:

• Segment-level operating profit, not just revenue: watch U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International to see where profit is actually being generated and which segments are growing fastest.
• Gross profit and operating margin trends: small basis-point moves are meaningful at McKesson's scale. Look at branded vs. generic mix and generic price deflation commentary in the MD&A.
• Specialty and oncology momentum: these are key strategic growth areas; management commentary on provider networks, biopharma services, and specialty distribution signals future profit mix.
• Working capital and free cash flow: changes in receivables, inventories, and payables (the "draft accommodation" / supplier financing dynamics) can swing operating cash flow materially quarter to quarter.
• Opioid and other litigation disclosures: review the legal proceedings and commitments/contingencies notes for settlement payment schedules and any new claims.
• Customer concentration: large pharmacy chain relationships and group purchasing arrangements; the loss or renegotiation of a major customer contract is material.
• 8-K filings: watch for guidance updates, large acquisitions or divestitures (McKesson actively reshapes its portfolio), buyback authorizations, and management changes.

Key Risks

• Razor-thin margins: the distribution model leaves little room for error; small disruptions in pricing, mix, or sourcing economics can disproportionately affect profit.
• Customer concentration: a meaningful share of revenue comes from a small number of large pharmacy and provider customers, so contract renewals and renegotiations carry significant leverage against McKesson.
• Litigation and regulatory exposure: ongoing and potential opioid-related liabilities, DEA controlled-substance reporting obligations, and the risk of fines or compliance actions remain a structural overhang.
• Drug pricing and policy reform: changes to U.S. drug pricing rules, PBM regulation, Medicare/Medicaid reimbursement, and generic price deflation can compress fees and margins.
• Manufacturer relationships: distribution and service fees depend on negotiations with drug makers; shifts in manufacturer go-to-market strategies (including direct distribution) could erode the distributor's role.
• Supplier and inventory risk: drug shortages, recalls, supply-chain interruptions, and inventory write-downs can affect availability and economics.
• Acquisition integration: McKesson is acquisitive, especially in specialty and oncology, which carries integration, goodwill, and execution risk.
• Concentrated industry scrutiny: as one of three dominant distributors, McKesson faces ongoing antitrust and public-policy attention.

Frequently Asked Questions